Semagacestat - CAS 425386-60-3
Catalog number: 425386-60-3
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Semagacestat is an inhibitor of the γ-secretase complex that blocks the production of Aβ38 (IC50= 12.0 nM), Aβ40 (IC50= 12.1 nM), and Aβ42 (IC50= 10.9 nM) from H4 human glioma cells stably overexpressing human wild-type APP into the culture medium. In vitro: blocks the production of Aβ38 (IC50= 12.0 nM), Aβ40 (IC50= 12.1 nM), and Aβ42 (IC50= 10.9 nM) without affecting cell viability. In vivo: decreases hippocampal levels of both Aβ42 and Aβ40 at 10 mg/kg (22-23% reduction) and 30 mg/kg (36-41% reduction) and increases β-CTF at 0.3-10 mg/kg in a dose dependent manner with no inhibition on the processing of other γ-secretase substrates, such as Notch, N-cadherin or EphA4, in the brain, but impairs normal cognition in wild-type mice and 3-month-old Tg2576 mice failing to restore cognitive deficits in the Y-maze test.
Brife Description:
A potent inhibitor of γ-secretase; Blocks Notch signaling (IC50 = 14.1 nM)
White to off-white solid
(2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide; LY 411,575; LY 411575; LY 450139; LY-411,575; LY-411575; LY411,575; LY411575; LY450139; N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide; N2-(2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-(5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)alaninamide; Semagacestat; 425386-60-3
Soluble to 70mg/mL in DMSO, to 41mg/mL in Ethanol
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -45℃ for long term (months to years).
Boiling Point:
681.904℃ at 760 mmHg
1.221 g/cm3
Canonical SMILES:
1.Validation and Clinical Utility of ELISA Methods for Quantification of Amyloid-β of Peptides in Cerebrospinal Fluid Specimens from Alzheimer’s Disease Studies.
Lachno DR1, Evert BA, Maloney K, Willis BA, Talbot JA, Vandijck M, Dean RA. J Alzheimers Dis. 2015;45(2):527-42.
The aim of this study was to validate assays for measurement of amyloid-β (Aβ) peptides in cerebrospinal fluid (CSF)specimens according to regulatory guidance and demonstrate their utility with measurements in specimens from Alzheimer’s disease (AD) studies. Methods based on INNOTEST(®)β-AMYLOID(1-42) and prototype INNOTEST(®)β-AMYLOID(1-40) ELISAkits were developed involving pre-analytical sample treatment with Tween-20 for reliable analyte recovery.Validation parameters were evaluated by repeated testing of CSF pools collected and stored in the same manner as clinical specimens. Intra- and interassay coefficients of variation were ≤11% and relative accuracy was within ± 10% for both analytes. Dilutional linearity was demonstrated for both analytes from a spiked CSF pool, but not from a non-spiked native CSF pool. Recovery of standard Aβ peptide spikes standard ranged from 77% to 93%. No interference was observed from the investigational drugs LY2811376, LY2886721, LY3002813, or semagacestat.
2.A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS).
Wessels AM1, Siemers ER1, Yu P1, Andersen SW1, Holdridge KC1, Sims JR1, Sundell K1, Stern Y2, Rentz DM3, Dubois B4, Jones RW5, Cummings J6, Aisen PS7. J Prev Alzheimers Dis. 2015 Dec 1;2(4):227-241.
It is generally recognized that more sensitive instruments for the earliest stages of Alzheimer's disease (AD) are needed. The integrated Alzheimer's Disease Rating Scale (iADRS) combines scores from 2 widely accepted measures, the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living (ADCS-iADL). Disease progression and treatment differences as measured by the iADRS were analyzed using data from solanezumab EXPEDITION, EXPEDITION2, and EXPEDITION-EXT Studies; semagacestat IDENTITY Study; and donepezil ADCS - mild cognitive impairment (ADCS-MCI) Study. Psychometric properties of the iADRS were established through principal component analysis (PCA) and estimation of contributions of subscores and individual item scores to the iADRS total score. The iADRS performed better than most composites and scales in detecting disease progression and comparably or better than individual scales in detecting treatment differences.
3.Lessons from a failed γ-secretase Alzheimer trial.
De Strooper B1. Cell. 2014 Nov 6;159(4):721-6. doi: 10.1016/j.cell.2014.10.016.
γ-Secretase proteases have been associated with pathology in Alzheimer disease (AD), but we are just beginning to understand their basic mechanisms and physiological roles. A negative drug trial with a broad spectrum γ-secretase inhibitor in AD patients has severely dampened enthusiasm for the potential of pursuing γ-secretase research therapeutically. This pessimism is unwarranted: analysis of available information presented here demonstrates significant confounds for interpreting the outcome of the trial and argues that the major lessons pertain to broad knowledge gaps that are imperative to fill.
4.What lessons can be learned from failed Alzheimer's disease trials?
Toyn J1. Expert Rev Clin Pharmacol. 2015 May;8(3):267-9. doi: 10.1586/17512433.2015.1034690. Epub 2015 Apr 10.
Trials missing primary efficacy end points raise the question of whether the choice of drug or the limitations of disease biology were at fault. In some trials, drugs appear not to have achieved biochemical effect thresholds sufficient for clinical benefit. This suggests the need for improved drugs that are more active at tolerated doses. In other trials, it is unclear how the observed biomarker changes are related to potential efficacy. However, hints of efficacy from exploratory analyses support the idea that starting treatment earlier in the course of the disease might be more effective. A closer look at the failed trials will help de-risk future trials.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related γ-secretase Products

CAS 656810-87-6 MK-0752 sodium salt

MK-0752 sodium salt
(CAS: 656810-87-6)

MK-0752 sodium salt is a novel potent γ-secretase inhibitor. It is in clinical trial for treatment of several types of cancer.

CAS 749269-83-8 CHF 5074

CHF 5074
(CAS: 749269-83-8)

CHF5074, also known as CSP-1103, is a novel γ-secretase modulator. It could reduce Aβ42 and Aβ40 secretion, which IC50 value is 3.6 and 18.4 μM respectively. It...

LY-411575 isomer 3

LY-411575 isomer 3, is an isomer of LY411575, which is a potent, cell-permeable γ-secretase inhibitor (IC50= 0.078 nM/0.082 nM (in membrane-assay/in cell-based...

CAS 1172637-87-4 gamma-secretase modulator 1

gamma-secretase modulator 1
(CAS: 1172637-87-4)

gamma-secretase modulator 1 is a gamma-secretase modulator, useful for Alzheimer's disease.

CAS 209984-56-5 DBZ

(CAS: 209984-56-5)

DBZ, also called dibenzazepine, is a γ-secretase inhibitor to treat Alzheimer′s Disease, and it also inhibit Notch signaling.

CAS 425386-60-3 Semagacestat

(CAS: 425386-60-3)

Semagacestat is an inhibitor of the γ-secretase complex that blocks the production of Aβ38 (IC50= 12.0 nM), Aβ40 (IC50= 12.1 nM), and Aβ42 (IC50= 10.9 nM) fro...

CAS 1444006-79-4 ELND007

(CAS: 1444006-79-4)

ELND007 is a γ-secretase inhibitor.

CAS 51543-40-9 Flurizan

(CAS: 51543-40-9)

Flurizan, also called Tarenflurbil, is a nonsteroidal anti-inflammatory drug which inhibits γ-secretase activity leading to preventing the formation of the amyl...

CAS 471905-41-6 MK-0752

(CAS: 471905-41-6)

MK 0752, a potent, reversible inhibitor of γ-secretase (IC50 ~50 nM), reduces the cleavage of APP to Aβ40 in human neuroblastoma SH-SY5Y cells (IC50= 5 nM).

PF 3084014 hydrobromide

PF 3084014 hydrobromide, developed by Pfizer, is a potent γ-secretase inhibitor (in whole cell: IC50= 1.2 nM; in cell-free assaysand IC50= 6.2 nM).

TC-E 5006
(CAS: 1257395-14-4)

TC-E 5006, also called BIIB042, a potent γ-secretase modulator, which lowered Aβ42, increased Aβ38, but had little to no effect on Aβ40 levels both in vitro and...

CAS 1333990-84-3 ELND006

(CAS: 1333990-84-3)

ELND006 is one of the newest molecules to be reported on regarding the testing of the β-amyloid hypothesis. At the 2010 Alzheimer’s Association International Co...

CAS 1093978-89-2 gamma-secretase modulator 2

gamma-secretase modulator 2
(CAS: 1093978-89-2)

gamma-secretase modulator 2,a triazole derivative, a potent and selective γ-secretase modulator so as to selectively attenuate production of Aβ(1-42) and hence ...

(CAS: 443989-01-3)

GSI-136 is an amyloid precursor protein secretase inhibitor.

CAS 173550-33-9 Compound W

Compound W
(CAS: 173550-33-9)

Compound W, also called 3,5-bis(4-Nitrophenoxy)benzoic acid, a 3,3'-diiodothyronine sulfate cross-reactive substance, is an inhibitor of γ-secretase which cause...

CAS 1146699-66-2 BMS-708163

(CAS: 1146699-66-2)

BMS-708163, also called Avagacestat, is a potent, orally bioavailable inhibitor of γ-secretase that more potently inhibits the cleavage of APP (IC50s = 0.30 nM)...

CAS 769169-27-9 Begacestat

(CAS: 769169-27-9)

Begacestat is a selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase. Begacestat inhibits Abeta production with low nanomolar pote...

CAS 935525-13-6 BMS-433796

(CAS: 935525-13-6)

BMS-433796 is a γ-secretase inhibitor. Chronic dosing of BMS-433796 in Tg2576 mice suggested a narrow therapeutic window and Notch-mediated toxicity at higher d...

CAS 209986-17-4 Compound E

Compound E
(CAS: 209986-17-4)

Compound E is a cell-permeable inhibitor of γ-secretase (GSI), which is a multifunctional transmembrane protein complex enzymatically catalyzing the cleavage of...

CAS 62252-26-0 JLK 6

(CAS: 62252-26-0)

JLK 6, under the IUPAC name 7-amino-4-chloro-3-methoxyisochromen-1-one, an inhibitor of γ-secretase (IC50= between 10 μM-1 mM) that belongs to the class of isoc...

Chemical Structure

CAS 425386-60-3 Semagacestat

Quick Inquiry

Verification code

Featured Items